Aura Biosciences, Inc. (NASDAQ:AURA) CTO Sells $16,670.25 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) CTO Mark Plavsic sold 2,151 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $7.75, for a total transaction of $16,670.25. Following the sale, the chief technology officer now owns 209,456 shares of the company’s stock, valued at approximately $1,623,284. This represents a 1.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Aura Biosciences Stock Down 0.3 %

Shares of AURA opened at $7.63 on Friday. The stock has a market cap of $381.12 million, a P/E ratio of -4.41 and a beta of 0.29. The business’s 50 day moving average price is $8.01 and its 200-day moving average price is $8.74. Aura Biosciences, Inc. has a 52 week low of $6.63 and a 52 week high of $12.38.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Barclays PLC increased its holdings in shares of Aura Biosciences by 256.5% during the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock valued at $544,000 after acquiring an additional 43,897 shares in the last quarter. State Street Corp grew its position in Aura Biosciences by 3.7% during the 3rd quarter. State Street Corp now owns 754,803 shares of the company’s stock valued at $6,725,000 after purchasing an additional 26,841 shares during the last quarter. Geode Capital Management LLC increased its stake in Aura Biosciences by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock valued at $8,990,000 after purchasing an additional 39,379 shares in the last quarter. Wellington Management Group LLP purchased a new position in Aura Biosciences in the third quarter worth about $1,037,000. Finally, Franklin Resources Inc. lifted its stake in shares of Aura Biosciences by 14.8% in the third quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock worth $15,571,000 after buying an additional 215,597 shares in the last quarter. Hedge funds and other institutional investors own 96.75% of the company’s stock.

Analysts Set New Price Targets

AURA has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Aura Biosciences in a research report on Thursday, November 14th. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $23.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.